Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

289 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Buenos Aires Breast Cancer Symposium 2024: bridging basic and clinical research in breast cancer.
Abba M, Behbod F, Ceppi P, Chammas R, Clarke R, Dalotto T, De Siervi A, Gómez Abuin G, Gottifredi V, Hoadley KA, Jerry J, Juric D, Kordon E, Lanari C, Lee A, Mahmoud YD, Mandó P, Maurer J, Mauro F, Miller T, Muller WJ, Novaro V, Oesterreich S, Park C, Pettit S, Razavi P, Richer J, Roqué M, Rossi M, Salaberry PJ, Salatino M, Sciacca M, Vallone SA, Vilarullo RN, Vivanco M, Waisberg F, Welm A, Wolos VJ. Abba M, et al. Among authors: richer j. Medicina (B Aires). 2025;85(3):586-596. Medicina (B Aires). 2025. PMID: 40577145 Free article. English.
Ocular Findings as the Most Striking Manifestation of a SMAD3 Variant.
Villeneuve-Cloutier N, Boswell-Patterson CA, Bronicki L, Vincent KM, Wilk K, Yu AC, Graham GE, Richer J. Villeneuve-Cloutier N, et al. Among authors: richer j. Am J Med Genet A. 2025 Jun 4:e64124. doi: 10.1002/ajmg.a.64124. Online ahead of print. Am J Med Genet A. 2025. PMID: 40464278
Mainstreaming of clinical genetic testing: A conceptual framework.
Mackley MP, Richer J, Guerin A, Caluseriu O, Armstrong L, Blood KA, Bernier F, Boswell-Patterson C, Chard M, Costain G, Dyment D, Eaton A, Faghfoury H, Frosk P, Gillespie MK, Goh ES, Hayeems RZ, Hashemi B, Innes AM, Jackson M, Laberge AM, Limoges J, Marshall C, McMillan H, Nelson TN, Osmond M, Parboosingh J, Penney L, Prince B, Sawyer SL, Siu VM, Thomas MA, Turner L, Villeneuve-Cloutier N, Hartley T, Boycott KM. Mackley MP, et al. Among authors: richer j. Genet Med. 2025 May 22;27(8):101465. doi: 10.1016/j.gim.2025.101465. Online ahead of print. Genet Med. 2025. PMID: 40417744 Free article.
EYA3 regulation of NF-κB and CCL2 suppresses cytotoxic NK cells in the premetastatic niche to promote TNBC metastasis.
Rosenbaum SR, Hughes CJ, Fields KM, Purdy SC, Gustafson AL, Wolin A, Hampton D, Shrivastava NM, Turner N, Danis E, Ebmeier C, Spoelstra N, Richer J, Jedlicka P, Costello JC, Zhao R, Ford HL. Rosenbaum SR, et al. Among authors: richer j. Sci Adv. 2025 May 9;11(19):eadt0504. doi: 10.1126/sciadv.adt0504. Epub 2025 May 7. Sci Adv. 2025. PMID: 40333987 Free PMC article.
Neoadjuvant FOLF(IRIN)OX Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Multicenter Randomized Noncomparative Phase II Trial (PANACHE01 FRENCH08 PRODIGE48 study).
Schwarz L, Bachet JB, Meurisse A, Bouché O, Assenat E, Piessen G, Hammel P, Regenet N, Taieb J, Turrini O, Paye F, Turpin A, Souche FR, Laurent C, Kianmanesh R, Michel P, Vernerey D, Mabrut JY, Turco C, Truant S, Sa Cunha A; PANACHE01-FRENCH08-PRODIGE48 Investigators. Schwarz L, et al. J Clin Oncol. 2025 Jun 10;43(17):1984-1996. doi: 10.1200/JCO-24-01378. Epub 2025 Apr 4. J Clin Oncol. 2025. PMID: 40184561 Clinical Trial.
Sexual dimorphism in SMAD3 pathogenic variant-harbouring individuals.
Richer J, Velchev JD, Goobie S, Boswell-Patterson CA, van de Laar IMBH, Verhagen JMA, Wessels MW, Roos-Hesselink JW, Luyckx I, Al-Amodi H, Chu MWA, Laberge AM, Sadikovic B, Balci T, Verstraeten A, Loeys B. Richer J, et al. J Med Genet. 2025 Feb 26;62(3):199-205. doi: 10.1136/jmg-2024-110219. J Med Genet. 2025. PMID: 39746778
Interpretation and classification of FBN1 variants associated with Marfan syndrome: consensus recommendations from the Clinical Genome Resource's FBN1 variant curation expert panel.
Drackley A, Somerville C, Arnaud P, Baudhuin LM, Hanna N, Kluge ML, Kotzer K, Boileau C, Bronicki L, Callewaert B, Cecchi A, Dietz H, Guo D, Harris S, Jarinova O, Lindsay M, Little L, Loeys B, MacCarrick G, Meester J, Milewicz D, Morisaki T, Morisaki H, Murdock D, Renard M, Richer J, Robert L, Ouzounian M, Van Laer L, De Backer J, Muiño-Mosquera L. Drackley A, et al. Among authors: richer j. Genome Med. 2024 Dec 31;16(1):154. doi: 10.1186/s13073-024-01423-3. Genome Med. 2024. PMID: 39741318 Free PMC article.
Clinical and immune responses to neoadjuvant fulvestrant with or without enzalutamide in ER+/Her2- breast cancer.
Elias AD, Staley AW, Fornier M, Vidal GA, Alami V, Sams S, Spoelstra NS, Goodspeed A, Kabos P, Diamond JR, Shagisultanova E, Gallagher RI, Wulfkuhle JD, Petricoin EF, Zolman KL, McSpadden T, Jordan KR, Slansky JE, Borges VF, Gao D, Richer JK. Elias AD, et al. Among authors: richer jk. NPJ Breast Cancer. 2024 Oct 6;10(1):88. doi: 10.1038/s41523-024-00697-5. NPJ Breast Cancer. 2024. PMID: 39368973 Free PMC article.
Blocking Tryptophan Catabolism Reduces Triple-Negative Breast Cancer Invasive Capacity.
Kuo LW, Crump LS, O'Neill K, Williams MM, Christenson JL, Spoelstra NS, Roy MK, Argabright A, Reisz JA, D'Alessandro A, Boorgula MP, Goodspeed A, Bickerdike M, Bitler BG, Richer JK. Kuo LW, et al. Among authors: richer jk. Cancer Res Commun. 2024 Oct 1;4(10):2699-2713. doi: 10.1158/2767-9764.CRC-24-0272. Cancer Res Commun. 2024. PMID: 39311710 Free PMC article.
289 results